Nodular number as a prognostic indicator in hepatic resection for intermediate-stage hepatocellular carcinoma: An international multicenter observational study.

Authors

null

Han Liu

Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China

Han Liu , Zhong-Qi Fan , Ming-Da Wang , Matteo Serenari , Myron Schwartz , Zhong Chen , Ya-Hao Zhou , Xian-Ming Wang , Ting-Hao Chen , Jie Li , Cheng-Wu Zhang , Hong Wang , Wei-Min Gu , Ying-Jian Liang , Matteo Cescon , Guo-Yue Lv , Tian Yang

Organizations

Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China, Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China, Hepatobiliary Surgery and Transplant Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy, Liver Cancer Program, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Department of Hepatobiliary Surgery, Affiliated Hospital of Nantong University, Nantong, China, Department of Hepatobiliary Surgery, Pu’er People’s Hospital, Pu’Er, China, Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China, Department of General Surgery, Ziyang First People’s Hospital, Ziyang, Sichuan, China, Department of Hepatobiliary Surgery, Fuyang People’s Hospital, Fuyang, China, Department of General Surgery, Cancer Center, Division of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Huzhou, China, Department of General Surgery, Liuyang People’s Hospital, Liuyang, China, The First Department of General Surgery, The Fourth Hospital of Harbin, Harbin, China, Department of Hepatobiliary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, China

Research Funding

No funding sources reported

Background: The role of hepatic resection in treating Barcelona Clinic Liver Cancer (BCLC) intermediate-stage hepatocellular carcinoma (HCC) is a subject of ongoing debate. This study aims to assess the prognostic significance of the number of nodular HCC in patients undergoing hepatic resection for intermediate-stage (BCLC stage B) HCC. Methods: An analysis was conducted using data from a multicenter database of patients who underwent curative-intent resection for BCLC intermediate-stage HCC. Patients were classified into binodular and tri(+)nodular (≥ 3 nodules) groups based on the number of tumor nodules. Long-term overall survival (OS) and recurrence-free survival (RFS) were compared between these groups. Univariate and multivariate Cox-regression analyses identified risk factors for OS and RFS. Additional comparisons were made with outcomes in patients with uninodular large HCC (single nodule > 5 cm; BCLC stage A). Results: Of the 338 patients with BCLC intermediate-stage HCC, 187 (55.3%) had binodular and 151 (44.7%) had tri(+)nodular disease. Patients with binodular HCC showed significantly better median OS (49.6 months) and RFS (22.2 months) compared to those with tri(+)nodular HCC (33.5 and 13.7 months, P = 0.036 and 0.009, respectively), and outcomes comparable to those with uninodular large HCC (59.8 and 26.8 months, P = 0.144 and 0.311, respectively). Multivariate analyses indicated that binodular HCC was independently associated with improved OS and RFS following hepatic resection in BCLC intermediate-stage HCC. Conclusions: Patients with binodular HCC exhibit more favorable survival outcomes post-resection of BCLC intermediate-stage HCC compared to those with tri(+)nodular HCC, akin to outcomes observed in BCLC early-stage uninodular large HCC. These findings highlight the prognostic relevance of nodular number in stratifying and guiding surgical decisions for intermediate-stage HCC.

Comparisons of long-term outcomes among patients with intermediate-stage HCC between the binodular and tri(+)nodular groups.

N (%)Total
(n = 338)
Binodular Group (n = 187)Tri(+)nodular Group (n = 151)P
Death during the follow-up226 (66.9)120 (64.2)106 (70.2)0.248
Recurrence during the follow-up215 (63.6)114 (61.0)101 (66.9)0.306
Median OS (95% CI), months41.7 (31.9, 51.5)49.6 (39.3, 59.9)33.5 (25.3, 41.7)0.036
1-year OS rate, %81.482.979.5
3-year OS rate, %52.857.547.0
5-year OS rate, %39.844.733.4
Median RFS (95% CI), months18.2 (14.2, 22.2)22.2 (16.2, 28.2)13.7 (9.9, 17.4)0.009
1-year RFS rate, %60.464.755.0
3-year RFS rate, %35.240.029.4
5-year RFS rate, %26.231.020.3

CI, confidence interval; OS, overall survival; RFS, recurrence-free survival.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Local-Regional Disease

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr e16271)

DOI

10.1200/JCO.2024.42.16_suppl.e16271

Abstract #

e16271

Abstract Disclosures